Last reviewed · How we verify
Dyspareunia
Approved treatments
- Intrarosa
- Premarin · Pfizer
- Intrarosa · Center for Vulvovaginal Disorders
- Synestrol · Johnson & Johnson
- Osphena · Duchesnay
Osphena works by binding to estrogen receptors, specifically targeting estrogen receptor beta, to provide relief from symptoms of atrophic vulva and dyspareunia. - Premarin · Pfizer
Conjugated estrogens bind to nuclear estrogen receptors in estrogen-responsive tissues, modulating gonadotropin secretion and reducing elevated LH and FSH in postmenopausal women. - Dehydroepiandrosterone · National Institute of Dental and Craniofacial Research (NIDCR)
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Dyspareunia patent landscape — cliff calendar, originator estates, attackable patents
- Dyspareunia treatment landscape brief
- Dyspareunia treatment updates RSS
Frequently asked questions about Dyspareunia
What drugs treat Dyspareunia?
Tracked treatments include Intrarosa, Premarin, Synestrol, Osphena, Dehydroepiandrosterone.
What is the treatment for Dyspareunia?
Standard treatment for Dyspareunia includes Intrarosa, Premarin, Synestrol, Osphena, Dehydroepiandrosterone. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Dyspareunia patent cliff · Dyspareunia CI report
- Treatment: Intrarosa
- Treatment: Premarin · Pfizer
- Treatment: Intrarosa · Center for Vulvovaginal Disorders
- Treatment: Synestrol · Johnson & Johnson
- Treatment: Osphena · Duchesnay
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing